Functional and genetic evidence that nucleoside transport is highly conserved in Leishmania species: Implications for pyrimidine-based chemotherapy by Alzahrani, Khalid J.H. et al.
lable at ScienceDirect
International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 206e226Contents lists avaiInternational Journal for Parasitology:
Drugs and Drug Resistance
journal homepage: www.elsevier .com/locate/ i jpddrFunctional and genetic evidence that nucleoside transport is highly
conserved in Leishmania species: Implications for pyrimidine-based
chemotherapy
Khalid J.H. Alzahrani a, b, 1, Juma A.M. Ali a, c, 1, Anthonius A. Eze a, d, Wan Limm Looi a,
Daniel N.A. Tagoe a, e, Darren J. Creek f, Michael P. Barrett a, e, Harry P. de Koning a, *
a Institute of Infection, Immunity and Inﬂammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
b Department of Clinical Laboratory, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
c Al Jabal Al Gharbi University, Gharyan, Libya
d Department of Medical Biochemistry, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria
e Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
f Department of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australiaa r t i c l e i n f o
Article history:
Received 14 November 2016
Received in revised form
14 April 2017
Accepted 18 April 2017
Available online 20 April 2017
Keywords:
Leishmania
Pyrimidine metabolism
Uracil transporter
Metabolomics
Nucleoside transporter
5-ﬂuorouracil
Pyrimidine chemotherapy* Corresponding author. Institute of Infection, Imm
lege of Medical, Veterinary and Life Sciences, Sir Graem
of Glasgow, 120 University Place, Glasgow G12 8TA, U
E-mail address: Harry.de-Koning@glasgow.ac.uk (H
1 These authors contributed equally to this study.
http://dx.doi.org/10.1016/j.ijpddr.2017.04.003
2211-3207/© 2017 The Authors. Published by Elsevier
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Leishmania pyrimidine salvage is replete with opportunities for therapeutic intervention with enzyme
inhibitors or antimetabolites. Their uptake into cells depends upon speciﬁc transporters; therefore it is
essential to establish whether various Leishmania species possess similar pyrimidine transporters
capable of drug uptake. Here, we report a comprehensive characterization of pyrimidine transport in
L. major and L. mexicana. In both species, two transporters for uridine/adenosine were detected, one of
which also transported uracil and the antimetabolites 5-ﬂuoruracil (5-FU) and 5F,20deoxyuridine
(5F,20dUrd), and was designated uridine-uracil transporter 1 (UUT1); the other transporter mediated
uptake of adenosine, uridine, 5F,20dUrd and thymidine and was designated Nucleoside Transporter 1
(NT1). To verify the reported L. donovani model of two NT1-like genes encoding uridine/adenosine
transporters, and an NT2 gene encoding an inosine transporter, we cloned the corresponding L. major
and L. mexicana genes, expressing each in T. brucei. Consistent with the L. donovani reports, the NT1-like
genes of either species mediated the adenosine-sensitive uptake of [3H]-uridine but not of [3H]-inosine.
Conversely, the NT2-like genes mediated uptake of [3H]-inosine but not [3H]-uridine. Among pyrimidine
antimetabolites tested, 5-FU and 5F,20dUrd were the most effective antileishmanials; resistance to both
analogs was induced in L. major and L. mexicana. In each case it was found that the resistant cells had lost
the transport capacity for the inducing drug. Metabolomics analysis found that the mechanism of action
of 5-FU and 5F-20dUrd was similar in both Leishmania species, with major changes in deoxynucleotide
metabolism. We conclude that the pyrimidine salvage system is highly conserved in Leishmania species -
essential information for the development of pyrimidine-based chemotherapy.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leishmaniasis is a neglected tropical disease caused by at least
21 species of obligate intracellular parasites of the genusunity and Inﬂammation, Col-
e Davies Building, University
nited Kingdom.
.P. de Koning).
Ltd on behalf of Australian Society fLeishmania, and is transmitted by more than 30 species of female
sand-ﬂies from the genera Phlebotomus (Old World) or Lutzomyia
(New World) (Rodrigues et al., 2014). The disease remains a major
cause of morbidity and mortality worldwide that has been classi-
ﬁed into three main categories on the basis of clinical symptoms:
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and
mucocutaneous leishmaniasis (MCL) (Alvar et al., 2012). Due, in
part, to the fact that leishmaniasis with various clinical manifes-
tations is caused by different species, treatment of the disease is
still complicated, and often unsatisfactory (Croft and Olliaro, 2011;
Sundar and Chakravarty, 2013). Nucleotide metabolism providesor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
Nonstandard abbreviations
5-FURes 5-Fluorouracil resistant cells
5-F20dURes 5-Fluoro-20-deoxyuridine resistant cells
5-FU 5-Fluorouracil
5F-20dUrd 5-Fluoro-20-deoxyuridine
5F-Urd 5-Fluorouridine
5F-20dCtd 5-Fluoro-20-deoxycytidine
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parasites are unable to synthesize the purine ring de novo and rely
solely on salvage mechanisms for these important nutrients (De
Koning et al., 2005). Nonetheless, purine analog-based chemo-
therapy has not emerged against kinetoplastid parasites due to
redundancy of the interconversion pathways, making inhibition of
single enzymes often ineffective (Lüscher et al., 2007a, 2013; Berg
et al., 2010a). For the major protozoan pathogens most of the pu-
rine nucleoside and nucleobase transporters e which also some-
times exhibit a secondary transport activity for pyrimidines e have
been cloned, and all of these transporters belonged to the Equili-
brative Nucleoside Transporter (ENT) family (e. g. Vasudevan et al.,
1998; Chiang et al., 1999; Burchmore et al., 2003; Sanchez et al.,
2004; De Koning et al., 2005; Quashie et al., 2008). In contrast to
purines, kinetoplastid parasites are known to possess both salvage
and biosynthesis routes for pyrimidines (Wilson et al., 2012; Ali
et al., 2013a, 2013b). It has recently been demonstrated that
although both functions are important for infection, neither func-
tion is absolutely essential (Wilson et al., 2012; Ali et al., 2013b).
Although no single Leishmania purine or pyrimidine transporter
can be considered essential (Ortiz et al., 2007; Wilson et al., 2012),
they are vital links in the delivery of any nucleoside-based
chemotherapy to these parasites. The ﬁrst purine transporter
genes to be identiﬁed from any parasite were LdNT1 (Vasudevan
et al., 1998) and LdNT2, which were cloned from L. donovani
(Carter et al., 2000). NT1 mediates the uptake of adenosine and the
pyrimidine nucleosides uridine and thymidine, whereas NT2 rec-
ognizes the 6-oxopurine nucleosides inosine, guanosine, and xan-
thosine (Carter et al., 2001; Boitz et al., 2012). NT1 and NT2 also
serve as the primary conduits for uptake of the antileishmanial
adenosine analog tubercidin (7-deazaadenosine) and the anti-
leishmanial inosine analog formycin B, respectively (Vasudevan
et al., 1998; Carter et al., 2000), but the pharmacological exploita-
tion of these transporters has not been investigated further. In
addition, two purine nucleobase transporter genes have been
described in L. major, encoding the broad speciﬁcity nucleobase
transporter LmajNT3 active in promastigotes (Sanchez et al., 2004),
and the acid-activated LmajNT4 that is presumed to be mainly
functional in the intracellular amastigotes (Ortiz et al., 2009). It is
assumed that LmajNT3 and LmajNT4 correspond to the previously
characterized nucleobase transport activities in L. major promasti-
gotes and L. mexicana amastigotes, respectively (Al-Salabi et al.,
2003; Al-Salabi and De Koning, 2005), and that there are at a
minimum some differences between nucleoside/nucleobase
transport in the promastigote and amastigote stages (Ghosh and
Mukherjee, 2000; De Koning et al., 2005). Finally, a uracil-speciﬁc
transporter designated LmU1 was characterized in L. major pro-
mastigotes (Papageorgiou et al., 2005), but unlike the NT1-4
nucleoside and purine nucleobase transporters, which are mem-
bers of the Equilibrative Nucleoside Transporter (ENT) family, the
gene encoding this transporter is unknown and believed to be of a
different gene family (De Koning, 2007).There remain many caveats to the pharmacological exploitation
of the purine and/or pyrimidine salvage pathways for anti-
leishmanial chemotherapy, including whether there are signiﬁcant
differences in nucleoside transport activities between the various
Leishmania species, what antimetabolites might be transported by
Leishmania nucleoside transporters, or what metabolic activation
steps might follow the uptake of pyrimidine antimetabolites. In this
study we address some of these issues and ﬁnd that (1) nucleoside
transport is highly similar in multiple Leishmania species; (2) that
the substrate binding of the LmajNT1 transporter depends on in-
teractions with the 2-keto and N3 positions of the pyrimidine ring
and the 30 and 50 hydroxyl groups of the ribose moiety; and that (3)
the antimetabolite 5-ﬂuoro-20-deoxyuridine (5F-20dUrd) is princi-
pally converted to 5F-dUMP, by thymidine kinase, causing the in-
hibition of thymidylate synthase and the consequent disruption of
deoxynucleotide metabolism; 5-ﬂuorouracil is ﬁrst converted to
5F-20dUrd and thence to 5F-dUMP.
2. Materials and methods
2.1. Kinetoplastid strains and cultures
Promastigotes of L. mexicana (MNY/BZ/62/M379 strain) and
L. major (Friedlin strain) were grown in HOMEM medium (Gibco,
Paisley, UK) (pH 7.4) supplemented with 10% fetal bovine serum
(FBS) (Gibco) 1% Penicillin/Streptomycin antibiotic (Gibco) at 25 C
as described (Al-Salabi et al., 2003). The T. b. brucei strain B48
(Bridges et al., 2007) was used throughout as the expression system
for Leishmania transporters, and maintained exactly as described
previously in HMI-9 medium with 10% FBS (Gibco) under a 5% CO2
atmosphere at 37 C (Vodnala et al., 2013). This strain is derived
from a Lister 427 clone from which the aminopurine transporter
TbAT1 has been deleted (Matovu et al., 2003) and was further
adapted to high levels of pentamidine, causing it to additionally
lose the High Afﬁnity Pentamidine Transporter (HAPT1) activity,
encoded by the gene TbAQP2 (Munday et al., 2014).
2.2. Plasmid construction and transfection
Plasmid construction and transfectionwas performed according
to Munday et al. (2013). The nucleoside transporter genes were
isolated from L. mexicana and L. major. The sequences of these genes
displayed a high degree of similarity to the known L. donovani
nucleoside transporter genes (LdNT1.1, LdNT1.2 and LdNT2;
Table S1). Sincewe could not differentiate between NT1.1 and NT1.2
genes in L. major and L. mexicana because both genes are highly
similar to both LdNT1.1, LdNT1.2, we designated these genes as
NT1A and NT1B (Table S1). The primers used in this study (Table S2)
were designed to ﬂank the gene of interest, one complementary to
the sequence upstream of the 50 end and the other complementary
to the sequence downstream of the 30 end. All of the nucleoside
transporters genes were PCR-ampliﬁed from genomic DNA of each
strain using the high-ﬁdelity proof-reading polymerase Phusion
(New England Biolabs) and cloned into the pGEMTeasy (Promega)
vector prior to Sanger sequencing (Source BioScience, Glasgow,
UK). For each gene, six independent clones were sequenced and
veriﬁed as correct. After conﬁrming the identity of each gene, the
nucleoside transporter genes (LmajNT1A, LmajNT1B, LmajNT2,
LmexNT1A, LmexNT1B, and LmexNT2) were ligated into the
expression vector pHD1336 (Biebinger et al., 1997) and then were
linearized with NotI digestion. All genes were veriﬁed by Sanger
sequencing, prior to transfection into T. b. brucei clone B48. B48
parasites (1  107 cells) were washed into Human T Cell buffer for
transfection using the desired cassette with an Amaxa Nucleofector
using programX-001. Cells were transferred into pre-warmed HMI-
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Following recovery, transfectants were grown and cloned in se-
lective medium containing 5 mg ml1 blasticidin S using limiting
dilution.2.3. Quantitative real-time PCR (qRT-PCR)
The experiment was performed exactly as described previously
(Ali et al., 2013b). Primers for qRT-PCR were designed using
Primer3® (Table S3). RNA isolated from T. b. brucei B48 strains and
Leishmania species was quantiﬁed using a NanoDrop device; 2 mg of
RNA was diluted in RNase-free water to a total volume of 25 ml
200 ng of RNA from each generated and control cell line, were used
for the production of complementary DNA (cDNA) using a Reverse-
Transcriptase (RT) kit (Primerdesign, UK). For each sample the
cDNA was diluted with RNase free water to 20 ng/ml for qRT-PCR.
Ampliﬁcation of cDNA was performed in a 7500 Real Time PCR
System (G-STORM, Thermo Scientiﬁc). The dissociation curve was
used to ensure the ampliﬁcation of only one product; samples
without RT or cDNA were used as controls. The constitutively
expressed gene GPI8 was used as an internal control (Wilson et al.,
2012). The DDCT method was used for relative quantiﬁcation (RQ)
using T. b. b. B48 cells in HMI-9 as a calibrator for the nucleoside
transporter genes expressed in T. b. b. B48, and using L. mexicana
promastigotes as a calibrator for the expression level of nucleoside
transporters genes in L. mexicana amastigotes. Data were analyzed
using Applied Biosystems 7500 SDS Real-Time PCR systems
software.2.4. Drug sensitivity assays
Sensitivity assays of Leishmania strains to various drugs using
the viability dye resazurin (Alamar Blue) (Sigma-Aldrich) were
performed using a protocol adapted from R€az et al. (1997), as
described (Al-Salabi et al., 2003; Gould et al., 2008). Pentamidine
and diminazene were used as non-nucleoside controls and were
obtained from Sigma-Aldrich, as were many purines, pyrimidines,
and analogs, with the exceptions of 2-thiouridine and 4-thiouridine
(TriLink BioTechnologies, San Diego, CA); 50-deoxyuridine, and 20-
30-dideoxyuridine (Carbosynth, Compton, UK); 5-ﬂuoro-20-deoxy-
uridine (Fluka); and 2-thiouracil (ICN Biomedicals, Cambridge, UK).
A preliminary promastigote culture was diluted to a density of
2  106 cells/ml, of which 100 ml was added to wells of 96-well
plates pre-loaded with 100 ml of doubling dilutions of test com-
pounds, resulting in a ﬁnal density of 1 106 cells/ml; the dilutions
were over 2 rows of the plate (23 concentrations), with the last well
containing only medium and serving as the no-drug control. The
plates were incubated at 25 C for 72 h before adding the Alamar
Blue dye (20 ml of 12.5 mg resazurin sodium salt (Sigma) in 100 ml
phosphate buffered saline (PBS; pH 7.4)). Since Leishmania parasites
metabolize the Alamar Blue dye slower than trypanosomes (Gould
et al., 2008), the cells were incubated with the dye for a further
period of 48 h before measuring the ﬂuorescence, using a FLUOstar
Optima ﬂuorimeter (BMG Labtech) at wavelengths of 544 nm for
excitation and 620 nm for emission. 50% effective concentrations
(EC50) were calculated using the equation for a sigmoidal curve
with variable slope using Prism 5.0 (GraphPad software Inc, Cali-
fornia, USA) software; extrapolation of incomplete curves was used
when >50% inhibition was achieved, using the minimum ﬂuores-
cence in the curve with the control drug (pentamidine) as the sole
constraint. Each experiment was performed independently at least
4 times; statistical signiﬁcance was determined using Student's
unpaired t-test.2.5. Transport assays
Using the standard uptake technique as described for T. brucei
and Leishmania species (Wallace et al., 2002; Al-Salabi and De
Koning, 2005; Gudin et al., 2006), the dose- or time-dependent
uptake of radiolabeled permeants was investigated. The following
radiolabels and speciﬁc activities were used: [3H]-thymidine (Per-
kin Elmer; 56.6 Ci/mmol); [3H]-adenosine (American Radiolabeled
Chemicals UK; 40 Ci/mmol); [3H]-uridine (American Radiolabeled
Chemicals UK; 30 Ci/mmol); [3H]-uracil (Perkin Elmer; 24.8 Ci/
mmol); [3H]-inosine (American Radiolabeled Chemicals UK; 20 Ci/
mmol); [3H]-5-ﬂuorouracil (Moravek; 20 Ci/mmol).
Brieﬂy, cells in the mid-to-late logarithmic stage of growth were
harvested by centrifugation for 10 min at 1500g. The cells were
washed twice with transport assay buffer (AB: 33 mM HEPES,
98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mMMgSO4, 5.8 mM
NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose, pH 7.3),
resuspended at a density of 108 cells ml1 in AB, and left for
20e30 min at room temperature to recover from centrifugation
stress. One hundred microliters of cell suspensionwas incubated at
ambient temperature for a predetermined time with 100 ml radio-
labeled test compound, in the presence or absence of unlabeled
substrate or other competitive inhibitors. The incubation was
terminated by the addition of ice-cold stop solution (AB containing
saturating levels, usually 10 mM, of unlabeled permeant) and
centrifugation through oil for 1 min at 13,000  g. Trapped extra-
cellular radioactivity was determined as the amount of radiolabel
associated with the cell pellet in the presence of 1 mM permeant
(i.e. saturation of all high afﬁnity transport activities), and sub-
tracted. Radioactivity was determined by liquid scintillation
counting in a Beckman LS6000 TA scintillation counter. Saturation
data, inhibition data, and time courses were plotted to equations
for linear or non-linear regression (hyperbolic or sigmoid curves),
as appropriate. All experiments were performed in triplicate and on
at least three independent occasions.
2.6. Adaptation of Leishmania promastigotes to tolerance for
pyrimidine analogs
Promastigotes of the wild-type L. mexicana M379 and L. major
Friedlin strains were exposed to non-lethal concentrations
(0.5  EC50) of 5-ﬂuorouracil and 5-ﬂuoro-20-deoxyuridine. The
cells were then visually observed for viability and sub-passaged to
tolerated concentrations of the drugs. The procedure was repeated
until a high level of tolerance to the drug was obtained, essentially
as described for the adaptation of T. brucei to pentamidine (Bridges
et al., 2007), diminazene (Teka et al., 2011), curcumin analog AS-
HK014 (Changtam et al., 2010) and ﬂuorinated pyrimidines (Ali
et al., 2013a). After achieving a high level of resistance, clonal
populations were obtained by limiting dilution.
2.7. Metabolomics sample preparation and analysis
Metabolomics analysis of the Leishmania promastigotes was
undertaken in triplicate, exactly as described (Ali et al., 2013a).
Brieﬂy, cells were grown to log phase stage, resuspended at
2  106 cells/ml in 50 ml HOMEM/FBS and incubated 8 h with
100 mM of test compound (standard conditions) before transfer to a
50-ml centrifuge tube for instantaneous cooling (dry ice/ethanol
bath, 4 C) and centrifugation (2500 rpm, 10 min, 4 C). The pellet
was lysed with 200 ml of chloroform/methanol/water (1:3:1 v/v/v)
containing mass spectrometry standards, and vigorous mixing (1 h,
4 C); cell debris was removed by centrifugation and the metabolite
extracts were stored in HPLC vials at 80 C. Control samples were
prepared in parallel and included untreated cells, unused growth
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The analysis used a hydrophilic interaction liquid chromatography
(HILIC-LC) ﬁtted with a zwitterionic ZIC-pHILIC column (Merck
Sequant), coupled to high resolution mass spectrometry (MS) using
a Thermo Q-Exactive, andmetabolomic data outputs were analyzed
using the IDEOM application (http://mzmatch.sourceforge.net/
ideom.php) with default parameters (Creek et al., 2012) exactly as
described (Ali et al., 2013a). The lower limit of detection was set to
500 intensity units for all reported metabolites, in order to prevent
spurious identiﬁcation of low level signals.
3. Results
3.1. Characterization of pyrimidine transporters in promastigotes of
L. mexicana
3.1.1. [3H]-Thymidine uptake in L. mexicana
L. donovani is known to express one pyrimidine nucleoside
transporter, LdNT1, which also transports adenosine (Vasudevan
et al., 1998; De Koning et al., 2005). In order to investigate
whether this model held true for L. mexicana, the uptake of [3H]-
thymidine was studied. Uptake of 1 mM [3H]-thymidine was linear
(r2 ¼ 0.98) over 30 s with a rate of
0.082 ± 0.005 pmol(107 cells)1s1, and was clearly saturable, as
transport in the presence of 1 mM unlabeled thymidine was not
signiﬁcantly different from zero (P ¼ 0.95) (Fig. 1A). Similarly, up-
take of 1 mM [3H]-thymidine was linear over 2 min (Fig. 1B),Fig. 1. Transport of 1 mM [3H]-thymidine by promastigotes of L. mexicana. (A,B). Uptake wa
thymidine (C). Frame A: rate at 1 mM was 0.082 ± 0.005 pmol(107 cells)1s1, r2 ¼ 0.98
signiﬁcantly different from zero (P ¼ 0.95). Frame B: rate at 1 mM was 0.051 ± 0.002 pmo
thymidine, the rate was not signiﬁcantly different from zero (P ¼ 0.67). (C) Michaelis-Me
thymidine uptake by unlabeled adenosine (C), uridine (,) and cytidine (:). Unit for trans
D; symbols represent the average of triplicate determinations in a single representative exallowing subsequent inhibition experiments to be conducted over
20 s, very much within the linear range and thus representing the
initial rate of uptake rather than a rate of metabolism. Care was
taken throughout this study that whenever inhibition constants
(Ki) or Michaelis-Menten constants (Km) were determined the
conditions used had been veriﬁed to bewell within the linear range
of uptake. Indeed, we did not observe non-linearity when studying
nucleoside or uracil transport in Leishmania promastigotes, even at
longer times and where there was a net-accumulation of radiolabel
over the external concentration. In no time course experiments
(whether shown in this paper or not) did runs tests show a sig-
niﬁcant deviation from linearity. This is likely because the rate of
metabolism of nucleosides and nucleobases is very fast in kineto-
plastids and therefore does not become rate limiting for uptake,
especially over very short intervals. Moreover, the uptake of both
nucleobases and nucleosides has been shown to be a secondary
active transport mechanism, using proton symport to accumulate
purines and pyrimidines highly efﬁciently (De Koning and Jarvis,
1997, 1998; De Koning et al., 1998; Stein et al., 2003).
The Michaelis-Menten constant (Km) for thymidine was deter-
mined to be 11.2 ± 2.4 mM (Fig. 1C; Table 1; n ¼ 3). This thymidine
transporter was inhibited by adenosine with sub-micromolar af-
ﬁnity (Ki ¼ 0.25 ± 0.4 mM), by uridine with low micromolar afﬁnity
(Ki ¼ 9.1 ± 0.6 mM) and by cytidine with mid-micromolar afﬁnity
(Ki¼ 82± 5 mM) (Fig.1D). The transporter had little or no afﬁnity for
inosine, uracil or hypoxanthine (Table 1) and is consistent with the
substrate speciﬁcity of LdNT1.s measured over various intervals in the presence (,) or absence of 1 mM unlabeled
2, signiﬁcantly non-zero P < 0.0001; for control with 1 mM thymidine, rate was not
l(107 cells)1s1, r2 ¼ 0.995, signiﬁcantly non-zero P < 0.0001; for control with 1 mM
nten saturation curve for the uptake of [3H]-thymidine. (D) Inhibition of 1 mM [3H]-
port was pmol(107 cells)1s in frames A and B, and pmol(107 cells)1s1 in frames C and
periment, and error bars represent SEM.
Table 1
Transport of adenosine and pyrimidines in Leishmania mexicana promastigotes.
Transporter LmexNT1 LmexUU1
radiolabel [3H]-thymidine [3H]-adenosine [3H]-uridinea [3H]-uracil
Km (mM) 11.2 ± 2.4 0.81 ± 0.16 13.3 ± 2.4 29.7 ± 4.4
Vmaxb 1.53 ± 0.28 1.11 ± 0.19 0.74 ± 0.13 0.088 ± 0.010
Vmax/Km 0.14 1.38 0.055 0.003
inhibitors (Ki, mM)
adenosine 0.25 ± 0.04 0.81 ± 0.16 0.39 ± 0.09 NDc
thymidine 11.2 ± 2.4 16.5 ± 0.4 9.98 ± 2.67 NDc
uridine 9.1 ± 0.6 16.8 ± 1.3 13.3 ± 2.4 2.0 ± 0.5
20deoxyuridine ND ND ND 9.3 ± 2.6
5F,20deoxyuridine 6.99 ± 0.11 NDc
cytidine 82 ± 5 149 ± 18 78.6 ± 15.1 ND
inosine 640 ± 34 1630 ± 134 1010 ± 190 ND
uracil >2500 >2500 >2500 29.7 ± 4.4
5FU ND ND >5000 56.3 ± 6.4
thymine ND ND ND 560 ± 190
cytosine ND ND ND >5000
hypoxanthine >1000 ND >1000 >500
adenine ND >1000 >1000 288 ± 67
For each radiolabel, Km values are listed in bold typeface and reproduced in the inhibitors table for easy reference.
ND, not done.
a Measured in the presence of 1 mM uracil.
b Expressed in pmol(107 cells)1s1.
c These values are estimated to be similar to those of LmexNT1, based on the observation that the Hill slope for inhibition of [3H]-uridine was approximately 1, and the
level of inhibition 100%.
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We next investigated the transport of [3H]-adenosine in
L. mexicana promastigotes, which according to the efﬁcient inhi-
bition of [3H]-thymidine by adenosine, should be taken up with
high afﬁnity. Transport of 0.1 mM [3H]-adenosine was linear over at
least 30 s with a rate of 0.21 ± 0.01 pmol(107 cells)1s1 (Fig. 2A)
and the Km value was determined as 0.81 ± 0.16 mM (Fig. 2B). Fig. 2C
shows the inhibition curves for adenosine (high afﬁnity), uridine
and thymidine (almost identical, low micromolar), and cytidine
(mid-micromolar afﬁnity). Adenosine transport was not inhibited
by adenine or uracil and only with very low afﬁnity by inosine
(1.6 ± 0.1 mM; Table 1). The kinetics showed no indication for more
than 1 transport activity for adenosine (100% inhibition by pyrim-
idine nucleosides; Hill slopes consistently near 1).
3.1.3. [3H]-uridine uptake in L. mexicana
Fig. 3A shows that 0.25 mM [3H]-uridine was taken up efﬁciently
and linearly over 120 s, with a rate ofFig. 2. Transport of [3H]-adenosine by L. mexicana promastigotes. (A) Transport of 0.1 mM [3H
0.1 mM was 0.21 ± 0.01 pmol(107 cells)1s1, r2 ¼ 0.988, signiﬁcantly non-zero P < 0.0001;
(P ¼ 0.001). (B) Michaelis-Menten saturation curve for the uptake of [3H]-adenosine using 0
Inhibition of 0.05 mM [3H]-adenosine uptake by unlabeled adenosine (-), thymidine (,), u
pmol(107 cells)1s1 in frames B and C; symbols represent the average of triplicate determ0.0042 ± 0.0002 pmol(107 cells)1s1. The Km for the uridine ﬂux
was determined to be 7.15 ± 0.90 mM (n ¼ 5). As shown in Fig. 3B,
the Hill slope for inhibition of [3H]-uridine uptake by uridine was
close to 1 (0.91 ± 0.09, n ¼ 5), and thus consistent with a one-
transporter model, but uracil inhibited only part of the ﬂux,
revealing the existence of a uracil-sensitive transporter
(Ki ¼ 25.7 ± 6.6 mM (n ¼ 5)) and a uracil-insensitive uridine
transporter. From the [3H]-uridine Hill slope it follows that both
transporters have a similar afﬁnity for uridine and Fig. 3C further-
more shows that both are similarly sensitive to thymidine, which
was able to inhibit 100% of uridine transport. The uracil-insensitive
transport could be studied in isolation by the inclusion of 1 mM
uracil in the transport assay buffer, blocking the uracil-sensitive
component (Fig. 3C), revealing that indeed the EC50 for thymidine
was similar for the uracil-sensitive and einsensitive uridine
transporters. Adenosine clearly inhibited both transporters with
near-equal afﬁnity, with a Hill slope close to 1 (Fig. 3B). The Km of
the uracil-insensitive transporter was subsequently determined to]-adenosine in the presence (,) or absence of 1 mM unlabeled adenosine (C). Rate at
for control with 1 mM adenosine, the rate was 0.0028 ± 4.4106 pmol(107 cells)1s1
.05 mM radiolabel and various concentrations of unlabeled adenosine up to 33.3 mM. (C)
ridine (C) and cytidine (◊). Unit for transport was pmol(107 cells)1 for frame A, and
inations in a single representative experiment, and error bars represent SEM.
Fig. 3. Transport of [3H]-uridine by L. mexicana promastigotes. (A) Transport of 0.25 mM [3H]-uridine was linear (r2 ¼ 0.992) over 120 s with a rate of
0.0043 ± 0.0002 pmol(107 cells)1s1 (C). In the presence of 5 mM uridine (,) transport was not signiﬁcantly different from zero (P ¼ 0.43). (B) Transport of 0.25 mM [3H]-uridine
was dose-dependently inhibited by unlabeled uridine (C), resulting in an apparently mono-phasic sigmoid curve that could be converted to a Michaelis-Menten saturation plot
(inset) to determine Km and Vmax values. Transport was inhibited by 48% by up to 2.5 mM uracil (,), and ~100% by adenosine (:). (C) Transport of 0.25 mM [3H]-uridine was
determined in the presence (C) or absence (,,:) of 1 mM unlabeled uracil in order to inhibit the uracil-sensitive component of uridine uptake. Inhibitors shown are uracil (:)
and thymidine (,,C). The dotted line indicates the level of uridine uptake in the presence of 1 mM uracil with zero thymidine added. (D) Transport of 0.25 mM [3H]-uridine in the
presence of 1 mM uracil was dose-dependently inhibited by adenosine (-), uridine (,) and cytidine (C). The uridine inhibition data was converted to a Michaelis-Menten
saturation plot (inset). The level of [3H]-uridine in the absence of uracil or other inhibitor is also indicated (:). Unit for transport was pmol(107 cells)1 for frame A and
pmol(107 cells)1s1 in frames B-D; symbols represent the average of triplicate determinations in a single representative experiment, and error bars represent SEM.
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adenosine andmid-micromolar afﬁnity for cytidine (Fig. 3D) clearly
established that this component is mediated by the same trans-
porter as that mediating thymidine and adenosine uptake. This is
thus, like LdNT1, an adenosine/uridine/thymidine transporter,
insensitive to purine or pyrimidine nucleobases or to sub-
millimolar concentrations of inosine (Table 1), and we hereby
designate it LmexNT1.
3.1.4. [3H]-Uracil uptake in L. mexicana
In order to study the uracil-sensitive uridine transporter we
next employed 1 mM [3H]-uracil, which was taken up linearly over
120 s (Fig. 4A) and we ﬁrst attempted to characterize the ﬂux over
just 20 s, but found that the relatively low levels of uptake resulted
in poor resolution of inhibition curves. We therefore extended the
time course and found that at the reduced concentration of 0.25 mM
linearity extended to at least 10 min (Fig. 4B), with a rate of
0.0020 ± 0.0002 pmol(107 cells)1s1. Transport of uracil over
4 min could thus be measured accurately and the Km was deter-
mined as 29.7 ± 4.4 mM (n ¼ 3), with 5-ﬂuorouracil displaying a
somewhat lower afﬁnity with a Ki of 56.3 ± 4.4 mM (n ¼ 3, P < 0.05)
(Table 1 and Fig. 4C). Consistent with the description of a uracil-
sensitive uridine transporter, above, [3H]-uracil transport was
dose-dependently inhibited by uridine (Ki ¼ 2.0 ± 0.5 mM), as well
as by 20-deoxyuridine (Ki ¼ 9.3 ± 2.6 mM; P < 0.05) (Fig. 4D).
However, it was consistently observed that both of these substrates,unlike uracil and 5-ﬂuorouracil, inhibited only approximately 85%
of [3H]-uracil transport (n ¼ 3). However, the ﬂux through a pre-
sumed uridine-insensitive uracil transporter was too small to be
characterized; it could be speculated that it is barely expressed in
the promastigote forms, at least under the culture conditions used.
We propose the designation L. mexicana uridine-uracil transporter
1 (LmexUUT1) for the uracil-sensitive uridine transporter here
described.
3.2. Characterization of pyrimidine transporters in promastigotes of
L. major
3.2.1. Thymidine transport in L. major
Transport of 0.25 mM [3H]-thymidine was linear over 10 min,
albeit with a very low rate of 0.0043 ± 0.0002 pmol(107 cells)1s1,
and completely inhibited by 1 mM unlabeled thymidine (Fig. 5A).
Subsequent experiments were performed with a 5 min incubation
time. Fig. 5B shows representative inhibition curves for the inhi-
bition of [3H]-thymidine transport by unlabeled uridine and
thymidine. Thymidine was the stronger inhibitor and, calculated
from the Michaelis-Menten saturation plots (unlabeled thymidine
in competition with [3H]-thymidine) (Fig. 5B, inset), an average Km
value of 30.7 ± 2.1 mM (n ¼ 5) was calculated. This compared to a Ki
value of 61.1 ± 7.4 mM (n ¼ 3) for uridine. The ﬁgure further illus-
trates that the Hill coefﬁcient of both sigmoid curves was greater
than the value of 1 associated with a one-transporter model. The
Fig. 4. Transport of [3H]-uracil by L. mexicana promastigotes. (A) Transport of 1 mM [3H]-uracil was linear over 120 s with a rate of 0.0030 ± 0.0002 pmol(107 cells)1s1 (C,
r2 ¼ 0.974; P < 0.0001) and was fully inhibited by 1 mM unlabeled uracil (,, not signiﬁcantly different from zero, P ¼ 0.73). (B) Transport of 0.5 mM [3H]-uracil was linear over
10 min with a rate of 0.0020 ± 0.0002 pmol(107 cells)1s1 (C, r2 ¼ 0.981; P ¼ 0.0011) and was 95% inhibited by 1 mM unlabeled uracil. (C) Transport of 0.5 mM [3H]-uracil was
dose-dependently inhibited by uracil (C) and by 5-ﬂuorouracil (,). The inhibition data for unlabeled uracil were converted to a Michaelis-Menten saturation plot (inset). (D)
Inhibition of 0.5 mM [3H]-uracil transport by uridine (:) and by 20-deoxyuridine (B). The level of inhibition by 1 mM unlabeled uracil is indicated (;). Unit for transport was
pmol(107 cells)1 for frames A and B, and pmol(107 cells)1s1 in frames C and D; symbols represent the average of triplicate determinations in a single representative experiment,
and error bars represent SEM.
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thymidine and uridine, respectively e indicative of a two-
component transport system with distinct but not greatly
different afﬁnities. In order to separate out the two transporters,
the thymidine inhibition data were redrawn using a Lineweaver-
Burke double reciprocal plot (Fig. 5C), revealing a high afﬁnity
thymidine transporter with an average Km of 4.2 ± 1.1 mM and Vmax
of 0.023 ± 0.003 pmol(107 cells)1s1, and a lower afﬁnity thymi-
dine transporter with a Km of 26.8 ± 5.4 mM and Vmax of
0.14 ± 0.03 pmol(107 cells)1s1 (both n ¼ 5). The approximately 6-
fold difference in apparent Km between the two transporters would
be consistent with the observed Hill slopes. Indeed, wewere unable
to separate the two transporters by inhibitor proﬁle, with several
inhibitors displaying 100% inhibition and Hill coefﬁcients near 1,
or incomplete inhibition at the highest concentration tested
(Fig. 5D). Adenosine was the highest afﬁnity inhibitor
(Ki ¼ 1.77 ± 0.21 mM, n ¼ 4) and in most cases inhibited 100% of
[3H]-thymidine transport, although in some cases a small per-
centage of the ﬂux appeared to resist adenosine inhibition (Fig. 5D).
Our interpretation of these results is that the two slightly different
thymidine transport activities here observed represent LmajNT1.1
and LmajNT1.2 (see below).
Table 2 presents an overview of inhibitors of [3H]-thymidine
transport in L. major promastigotes, which we treat as inhibitors of
the total thymidine transport activity constituted of LmajNT1.1 and
LmajNT1.2, as we were unable to measure each separately in wild-
type promastigotes and the kinetics strongly suggested that both
transporters were similarly sensitive to each inhibitor. Apart fromadenosine, Fig. 5D shows inhibition by several uridine analogs: 4-
thiouridine and 20-deoxyuridine displayed highly similar Ki
values to uridine (Table 2), showing that neither the 20 hydroxyl nor
the 4-position keto group of uridine are directly involved in in-
teractions with the transporter binding pocket. However, 2-
thiouridine displayed much lower afﬁnity for the NT1 trans-
porters (Fig. 5D), with a Ki value of 765 ± 68 mM versus
55.7 ± 5.4 mM for uridine. When these values are converted to the
Gibbs free energy of binding (DG0), it can be found that the dif-
ference in binding energy (d(DG0)) is 6.5 kJ/mol (Table 2), which can
be attributed to an interaction with the 2-position keto group with
the transporter binding site, following a method previously used to
construct binding models for other protozoan and human trans-
porters (De Koning and Jarvis, 1999;Wallace et al., 2002; De Koning
et al., 2003; Al-Salabi et al., 2007). Following similar reasoning, it
can be concluded that the 3-position pyrimidine nitrogen is also
involved in a positive interaction with the binding site, as 3-
deazauridine displayed much-reduced binding energy
(d(DG0) ¼ 10.4 kJ/mol). Furthermore, cytidine also displayed low
afﬁnity, but, since the 4-position keto group is not involved in
binding, this can be attributed to the change in N(3) protonation
state in cytidine versus uridine, consistent with a role for N(3).
Substitutions at position 5 of the pyrimidine ring (methyl, Fluor)
appear to be slightly favorable (Table 2) butmore importantly the 30
and 50 hydroxyl groups of the ribose moiety are clearly involved in
binding, given a d(DG0) of 14.1 kJ/mol comparing 30-deoxy-
thymidine with thymidine, and 4.9 kJ/mol comparing 5-
ﬂuorouridine with 5-ﬂuoro, 50-deoxyuridine, respectively. The
Fig. 5. Transport of 0.25 mM [3H]-thymidine by L. major promastigotes. (A) Transport of 0.25 mM [3H]-thymidine was linear for 10 min with a rate of
0.00030 ± 0.00002 pmol(107 cells)1s1 (C, r2 ¼ 0.986; P < 0.0001). In the presence of 1 mM unlabeled thymidine, transport was completely inhibited (,, not signiﬁcantly
different from zero, P ¼ 0.30). (B) Transport of [3H]-thymidine was inhibited by unlabeled uridine (,) and thymidine (C). The latter inhibition curve was also converted to a
Michaelis-Menten saturation curve (inset). (C) Lineweaver-Burk double reciprocal plot of the thymidine inhibition plot in panel B, showing the separation into two distinct transport
activities, a higher afﬁnity transport component with apparent Km 1.26 mM (B) and a lower afﬁnity component with apparent Km 17.1 mM in this experiment (-). Inhibition plots
for the transport of 0.25 mM [3H]-thymidine by adenosine (,), 4-thiouridine (C), 20deoxyuridine (◊) and cytidine (:). Unit for transport was pmol(107 cells)1 for frame A and
pmol(107 cells)1s1 in frames B-D; symbols represent the average of triplicate determinations in a single representative experiment, and error bars represent SEM.
Table 2
Transport of pyrimidine nucleosides in Leishmania major.
radiolabel LmajUUT1 LmajNT1
[3H]-uridine [3H]-uridine [3H]-thymidine
Km or Ki (mM) Km or Ki (mM) Km or Ki (mM) DG0 d(DG0)
Km (1) 3.12 ± 0.61 4.20 ± 1.09 30.7
Vmax (1)a 0.036 ± 0.004 0.023 ± 0.003
Km (2) 33.5 ± 7.3 26.9 ± 5.4 26.9
Vmax (2)a 0.15 ± 0.04 0.14 ± 0.03
Inhibitors (Ki, mM)
Uridine 55.7 ± 5.4 24.3 6.4 [tmd]
Thymidine 60.9 ± 8.4
Cytidine 1150 ± 108 16.8 7.5 [urd]
Adenosine 1.93 ± 0.49 1.77 ± 0.21 32.8 2.1 [tmd]
Inosine 0.50 ± 0.16 >1000 1990 ± 3050 15.4 17.4 [ado]
5-ﬂuorouridine 23.4 ± 1.3 26.4 2.1 [urd]
5-ﬂuoro,20-deoxyuridine 29.7 ± 2.1 25.8 0.6 [5F-urd]
5-ﬂuoro,50-deoxyuridine 168 ± 32 21.5 4.9 [5F-urd]
20-deoxyuridine 24.9 ± 8.6 112 ± 17 22.5 1.7 [urd]
30-deoxythymidine 1246 ± 44.5 16.6 14.1 [tmd]
20 ,30-dideoxyuridine >2500 >-15 <-9.3 [urd]
2-thiouridine 765 ± 68 17.8 6.5 [urd]
4-thiouridine 69.0 ± 18.1 23.8 0.5 [urd]
3-deazauridine 3670 ± 420 13.9 10.4 [urd]
thymine >1000
Uracil 2.65 ± 0.60 >1000 >1000
adenine 5.14 ± 2.25 >1000 >1000
a Expressed in pmol(107 cells)1s1.
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pyrimidine nucleoside binding to the NT1 transporters provides the
rationale for the complete lack of inhibition by up to 1 mM of the
nucleobases adenine, uracil and thymine (Table 2). Thus, four in-
teractions between the L. major NT1 transporter and uridine can be
identiﬁed, and these account energetically for the uridine DG0:
with keto position 2, nitrogen on position 3, and the hydroxyl
groups at positions 30 and 50. Three of those interactions (N3, 30OH
and 50OH) were also observed in the binding mode for uridine for
the Toxoplasma gondii AT2 and Trypanosoma brucei P1 transporters
(De Koning et al., 2003). In the case of TgAT2, the transporter also
engaged in a p-stacking interaction with the substrate, and in the
case of TbP1, no other interactions could be demonstrated,
explaining the relatively low afﬁnity for pyrimidines. TgAT2 also
interacted with the nitrogen on position 3 of the purine ring,
explaining its afﬁnity for both pyrimidine and purine nucleosides,
and indeed for both oxopurines inosine and guanosine and the
aminopurine adenosine (De Koning et al., 2003). From this example
it follows that LmajNT1 is likely to form a productive hydrogen
bond with the 6-position amine of adenosine and/or with the
protonated N1 residue - either would explain its selectivity for
aminopurines, as previously demonstrated for the T. brucei P2
transporter (Munday et al., 2015).
3.2.2. [3H]-Uridine transport in L. major
Transport of 0.25 mM [3H]-uridine in L. major promastigotesFig. 6. Transport of 0.25 mM [3H]-uridine by L. major promastigotes. (A) Uptake of [3H]-uridin
0.25 mM uridine was determined as 0.0024 ± 0.0002 pmol(107 cells)1s1 by linear regressio
presence of 1 mM unlabeled permeant. (B) Sigmoid inhibition curves for uridine (C) and ur
Conversion of the uridine inhibition data of panel B to a Lineweaver-Burk double reciprocal
low afﬁnity (:, r2 ¼ 0.981) components. Inset: zoom-in of main plot. (D) Sigmoid inhibitio
points showing the level of inhibition with 1 mM uridine (◊) and with 1 mM adenine þ 1 m
presence of 100 mM inosine (;, r2 ¼ 0.967, rate signiﬁcantly different from zero P ¼ 0.017 (
P ¼ 0.22 (F-test)) or without any inhibitors (C, r2 ¼ 0.993, rate signiﬁcantly different from ze
pmol(107 cells)1s1 in frames B-D; symbols represent the average of triplicate determinatproceeded at approximately half the rate of [3H]-thymidine trans-
port at the same concentration: Fig. 6A shows linear uptake of
0.25 mM [3H]-uridine over 15 min at a rate of
0.0024 ± 0.0002 pmol(107 cells)1s1. Like [3H]-thymidine trans-
port, two distinct components for [3H]-uridine transport were in
evidence, leading to a Hill coefﬁcient of 0.79 ± 0.11 for inhibition
with unlabeled uridine (Fig. 6B). As for thymidine transport, it was
possible to convert the inhibition plot to a single Michaelis-Menten
saturation plot (which gave an apparent Km of 7.3 ± 1.3 mM (n ¼ 3))
(Fig. 6B, inset), but a double reciprocal plot separated two compo-
nents (Fig. 6C) with apparent Km values of 3.1 ± 0.6 mM and
33.5 ± 7.3 mM (both n ¼ 3) (Table 2). Moreover, several inhibitors
displayed only partial inhibition, of just the high-afﬁnity trans-
porter, whereas several other inhibitors appeared to inhibit both
with similar afﬁnities. Uracil, for instance, inhibited only
77.2 ± 2.7%, with an average Hill coefﬁcient of0.93 ± 0.01(n¼ 4)e
indicative of a single transport system (Fig. 6B). Similar observa-
tions (Fig. 6D) were made for adenine (62.7 ± 1.7% inhibition; Hill
coefﬁcient is 1.25 ± 0.16) and inosine (Hill
coefﬁcient 1.09 ± 0.04; 70.8 ± 4.5% inhibition at 100 mM). Inosine
did appear to start to slightly inhibit the second transport
component at millimolar concentrations, but crucially the inhibi-
tion of 1 mM each of adenine and inosine was not additive, proving
that both fully inhibited the same transporter (Fig. 6D). The partial
inhibition of [3H]-uridine by inosine was further conﬁrmed by a
time course over 20 min (Fig. 6E), in which 100 mM inosinee in the presence (,) or absence (C) of 1 mM unlabeled uridine. The rate of uptake at
n (r2 ¼ 0.964; P ¼ 0.0005), but was not signiﬁcantly different from zero (P ¼ 0.94) in the
acil (,). The former was converted to a Michaelis-Menten saturation curve (inset). (C)
plot, showing separate linear regression lines for the high afﬁnity (,, r2 ¼ 0.999) and
n plots with inosine (,), adenosine (C) and adenine (;). Also shown are individual
M inosine (:). (E) Time course of 0.25 mM [3H]-uridine transport over 20 min in the
F-test)), in the presence of 1 mM uridine (,, rate not signiﬁcantly different from zero,
ro P ¼ 0.0035 (F-test)). Unit for transport was pmol(107 cells)1 for frames A and E, and
ions in a single representative experiment, and error bars represent SEM.
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of time-dependent uridine uptake in the presence of inosine was
signiﬁcantly non-zero (P ¼ 0.017), compared to the complete
inhibitory effect of 1 mM unlabeled uridine (P ¼ 0.22).
It is thus clear that L. major promastigotes, like L. mexicana,
express a uracil-sensitive uridine transporter, and accordingly we
designate this activity LmajUUT1. Both L. major uridine transport
activities were sensitive to the nucleosides thymidine and adeno-
sine and 20-deoxyuridine (Table 2). Fig. 6D shows the complete
inhibition of [3H]-uridine transport by adenosine, with a Ki value of
1.93 ± 0.49 mM. We conclude that L. major expresses two similar
adenosine/thymidine/uridine transporters, one of which is sensi-
tive to inhibition by uracil, adenine and inosine.
3.3. Molecular cloning and functional characterization of the
L. major and L. mexicana NT1 and NT2 nucleoside transporters
Open reading frames encoding members of the Equilibrative
Nucleoside Transporter family were identiﬁed in the L. mexicana
and L. major genomes (http://www.genedb.org/). The syntenic
genes to L. donovani NT1.1, NT1.2 and NT2 were cloned and intro-
duced into the clonal T. brucei cell line B48, which lacks both the
aminopurine transporter TbAT1 and the High Afﬁnity Pentamidine
Transporter HAPT1 (Bridges et al., 2007) using the expression
vector pHD1336 as described (Munday et al., 2013, 2015). Correct
integration of the linearized construct into the T. brucei genome
was conﬁrmed by PCR, and expression of all six genes (Table S1)
was conﬁrmed using qRT-PCR (Supplemental Fig. 1). Analysis of
NT1 and NT2 expression in promastigotes versus amastigotes of
L. mexicana revealed that both transporter types were similarly
expressed in these life cycle stages (Supplemental Fig. 2).
3.3.1. Functional characterization of the NT1A and NT1B
transporters
The activity of the Leishmania NT1 and NT2 transporters in
T. brucei clone B48 was assessed using [3H]-uridine and [3H]-ino-
sine, respectively. We ﬁrst assessed uridine and inosine uptake in
the non-transfected cells. Fig. 7A shows that uptake of 0.5 mM [3H]-
uridine in T. brucei B48was very slow, with a rate of just 1.98 105
± 1.9  106 pmol(107 cells)s1, and was strongly inhibited (75.7%)
by 250 mM uracil, and to a lesser extent by inosine (24.3%). The
combination of inosine and uracil fully inhibited the [3H]-uridine
transport. This is consistent with our previous characterizations of
purine and pyrimidine transporters in T. brucei, showing that uri-
dine can be taken up, although very inefﬁciently, by the U3 uracil
transporter (Ali et al., 2013a, 2013b), and also has a low afﬁnityFig. 7. Uridine and inosine transport in T. b. brucei strain B48. (A) Uptake of 0.5 mM [3H]-urid
inhibitors combined 100% inhibited [3H]-uridine uptake (,), as did 1 mM unlabeled uridin
inhibited by either 250 mM adenosine (,) or 1 mM unlabeled inosine (:). Unit for transp
determinations in a single representative experiment, and error bars represent SEM.(Ki ¼ 830 mM) for the P1 adenosine/inosine transporter (De Koning
and Jarvis, 1999). [3H]-inosine was transported far more robustly by
these cells, with the low concentration of 50 nM taken up at
0.0049 ± 0.0002 pmol(107 cells)s1 (Fig. 7B); the transport was
completely inhibited by 1 mM of either unlabeled inosine or
adenosine, consistent with our previous reports that inosine is only
taken up by the P1 purine nucleoside transporters (De Koning et al.,
1998; De Koning and Jarvis, 1999; Al-Salabi et al., 2007; Munday
et al., 2013).
Each of the Leishmania NT1-type transporters, LmexNT1A/B and
LmajNT1A/B, were separately transfected into B48 and [3H]-uridine
transport (Fig. 8AeD). In each case, uridine transport was mediated
by three transport activities: the T. brucei transporters U3 and P1,
and the heterologous Leishmania transporter. As the Leishmania
NT1 transporters are not inhibited by either uracil or inosine, the
combination of both was used to block all endogenous [3H]-uridine
transport, and the remaining uridine uptake represented uridine
uptake by the Leishmania transporter; the rate of uridine uptake by
U3þP1 follows from the subtraction of the uninhibited rate with
the rate in the presence of uracil and inosine. All four heterologous
transporters mediated uridine transport (Fig. 8AeD), and in each
case the transport was fully inhibited by 250 mM adenosine
(Supplemental Fig. S3). In the experiments shown, LmexNT1B
displayed the highest rate of [3H]-uridine transport. However, since
this is a complex function of its expression levels, translation efﬁ-
ciency and correct cellular localization among other factors, it
would not be right to assert, based solely on these data, that this
transporter is amore efﬁcient uridine transporter than the others. It
was veriﬁed for one sample transporter, LmajNT1, that it did not
mediate the transport of [3H]-inosine (Fig. 8E). In this experiment,
transport of 50 nM [3H]-inosine was assessed in the presence and
absence of 250 mM uridine, which fully inhibits the Leishmania NT1
transporters, but has little or no effect on either the P1 or U3
transporters (see above). As uridine had only a marginal effect on
[3H]-inosine transport in the cells expressing LmajNT1A, this
transporter did not mediate any substantial amounts of inosine
uptake.
3.3.2. Functional characterization of the Leishmania NT2
transporters expressed in B48
NT2 has, to date, only been investigated in Leishmania donovani,
and was found to be an adenosine-insensitive inosine/guanosine
(oxopurine nucleoside) transporter (Carter et al., 2000). We thus
took advantage of our T. brucei B48 expression system, in which all
endogenous inosine transport is highly sensitive to inhibition by
adenosine, to determine whether NT2 of L. major and L. mexicanaine (C) was inhibited 24.3% by 250 mM inosine (:) and 73.9% by uracil (-); the two
e (not shown for reasons of clarity). (B) Transport of 50 nM [3H]-inosine (C) was fully
ort was pmol(107 cells)1 in both frames; symbols represent the average of triplicate
Fig. 8. Uridine and inosine transport in T. brucei B48 transfected with Leishmania NT1-type transporters. (A) B48 transfected with LmexNT1A. Transport of 0.5 mM [3H]-uridine (C)
was partly inhibited by a combination of 250 mM uracil and 250 mM inosine (,); inhibition was complete with 1 mM uridine (:). (BeD) As (A) but for LmajNT1A, LmexNT1B and
LmajNT1B, respectively. (E) Transport of 50 nM [3H]-inosine by B48 transfected with LmajNT1A (C) was slightly inhibited by 250 mM uridine (,) and completely by 250 mM
adenosine (:) as well as by 1 mM inosine (not shown for clarity). Unit for transport was pmol(107 cells)1 in all frames; symbols represent the average of triplicate determinations
in a single representative experiment, and error bars represent SEM.
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way. B48 cells transfected with either LmajNT2 (Fig. 9A) or
LmexNT2 (Fig. 9B) displayed an [3H]-inosine transport activity
which was only partly inhibited by 250 mM adenosine. Since
adenosine, at these high concentrations, inhibits all inosine trans-
port ([3H-]-inosine at 50 nM) in untransfected B48 cells (Fig. 7B),
the remaining uptake rate in the presence of saturating concen-
trations of adenosine, must be mediated by the heterologously
expressed Leishmania transporter. From this experiment it is
evident that the Leishmania NT2 transporters are not sensitive to
inhibition by 250 mM adenosine. This was also directly shown using
L. mexicana promastigotes, where [3H]-inosine transport was not
inhibited at all by 1 mM adenosine (Fig. 9C). Furthermore, it could
be established that uridine is not a substrate for LmajNT2 either,
since transport of 0.5 mM [3H]-uridine in B48 expressing this
transporter was fully inhibited by a mixture of 250 mM adenosine
plus 250 mM uracil (Fig. 9D), which inhibits all endogenous T. brucei
uridine transport (Fig. 7A) but does not inhibit LmajNT2.
We thus conclude that the L. major and L. mexicana NT2 trans-
porters are indeed equivalent to the previously characterized
L. donovaniNT2 transporter, in that they are efﬁcient transporters of
low concentrations of inosine and insensitive to the LeishmaniaNT1
substrates adenosine and uridine.3.4. Sensitivity of Leishmania species to pyrimidine nucleoside and
nucleobase analogs
As pyrimidine nucleosides were salvaged much better by the
Leishmania NT1 transporters than by the nucleoside transporters of
T. brucei (Gudin et al., 2006; Ali et al., 2013a), we decided to assess
the antileishmanial effects of a selection of potentially cytotoxicpyrimidine analogs. The only pyrimidine analogs tested that
showed activity against promastigotes were 5-ﬂuorouracil (5-FU),
5-ﬂuoro-20-deoxyuridine (5F-20dUrd) and 5-ﬂuoro-20-deoxy-
cytidine (5F-20dCtd); these analogs displayed EC50 values at the
low-to-mid micromolar level (Table 3), with the thymidine analog
5F-20dUrd showing the most potent activity at ~1.5 mM against both
Leishmania species. Interestingly, the uridine analog 50-deoxyur-
idine showed much lower activity against L. mexicana promasti-
gotes, with an EC50 value of 461 ± 80 mM, which shows that all the
uridine analogs had poor antileishmanial activity whereas the 20-
deoxyuridine analog 5F-20dUrd, masquerading as a thymidine
analog, was several orders of magnitude more effective.
The effects of the ﬂuorinated pyrimidine analogs was similar
against L. mexicana and L. major promastigotes, an important
observation with respect to any drug development, with the
exception of 5-ﬂuorouridine, which displayed no activity against
L. mexicana at concentrations up to 5 mM, but killed promastigotes
of L. major at concentrations below 20 mM (Table 3; Supplemental
Fig. S4). This may indicate that, unlike L. mexicana, L. major is able
to metabolically incorporate 5F-uridine, probably through a uridine
or thymidine phosphorylase, which converts uridine and/or
thymidine to uracil, which is subsequently phosphoribosylated to
UMP by uracil phosphoribosyl transferase (Wilson et al., 2012). A
list of pyrimidine analogs without signiﬁcant activity against
Leishmania promastigotes (EC50 > 5 mM) is given in the legend to
Table 3. From this, it can be concluded that halogenation at position
5, other than with ﬂuorine, results in effective analogs (Cl/Br/I are
too large), that both 2-thio and 4-thio uridine are ineffective
(presumably not substrates for thymidine kinase or for the UP/
UPRT route); 5F-Ctd is ineffective (deamination would result in 5F-
Urd); 30-deoxy analogs are ineffective, including 20,30-
Fig. 9. Nucleoside transport by T. brucei B48 cells transfected with Leishmania NT2 transporters. (A) Transport of 50 nM [3H]-inosine by B48 cells expressing LmajNT2 (C). Transport
was 57% inhibited by 250 mM adenosine (,). Uptake in the presence of adenosine was 0.0023 ± 0.0001 pmol(107 cells)1s1 (slope signiﬁcantly different from zero P < 0.0001, F-
test; r2 ¼ 0.99), and 99.8% inhibited in the presence of 1 mM inosine (:; not signiﬁcantly different from zero, P > 0.05). (B) As frame (A), with LmexNT2. The rate of transport in the
presence of adenosine was 0.0023 ± 0.0003 pmol(107 cells)1s1 (slope signiﬁcantly different from zero P ¼ 0.0008, F-test; r2 ¼ 0.91), and 99.9% inhibited in the presence of 1 mM
inosine (:; not signiﬁcantly different from zero, P > 0.05). (C) Transport of 50 nM [3H]-inosine by L. mexicana promastigotes (C), in the presence of added 1 mM adenosine (,) or
1 mM inosine (:; not signiﬁcantly different from zero, P > 0.05). (D) Transport of 0.5 mM [3H]-uridine by B48 cells transfected with LmajNT2 (C), which was inhibited 95.2% by a
mixture of 250 mM adenosine and 250 mM uracil (,; rate not signiﬁcantly different from zero, F-test)). Inhibition by 1 mM uridine is also indicated (:). Unit for transport was
pmol(107 cells)1 in all frames; symbols represent the average of triplicate determinations in a single representative experiment, and error bars represent SEM.
Table 3
Sensitivity of 5-FU and 5F20dURes clones to ﬂuorinated pyrimidines.
L. mexicana L. major
WT Lmex5FURes Lmex5F20dURes WT Lmaj5FURes Lmaj5F20dURes
EC50 EC50 RF EC50 RF EC50 EC50 RF EC50 RF
5-FU 9.3 ± 0.6 1374 ± 123 147 1774 ± 301 190 8.5 ± 0.6 150 ± 5 17 12 ± 1.0 1.3
5F-20dUrd 1.4 ± 0.06 1.5 ± 0.2 1.07 >5000 >3500 1.7 ± 0.1 6.1 ± 0.5 3.6 381 ± 83 224
5F-20dCtd 17.3 ± 1.8 24 ± 0.9 1.4 >5000 >290 38 ± 1.7 17 ± 1.8 0.4 3870 ± 621 101
5F-Urd >5000 >5000 1 >5000 1 18 ± 1.6 110 ± 17 6.1 1230 ± 340 68
50dUrd 461 ± 80 ND e ND e 525 ± 46 ND e ND e
pentamidine 4.6 ± 0.2 5.0 ± 0.6 1.1 ND e 3.3 ± 0.2 ND e ND e
diminazene 7.4 ± 0.3 7.2 ± 1.4 0.97 13.9 ± 1.9 1.8 9.8 ± 0.3 10 ± 1.6 1.02 24.6 ± 1.5 2.5
All EC50 values were obtained using the Alamar blue assay and are given in mM. WT ¼ wild-type sensitive control strain. Resistance Factor ¼ IC50 (resistant clone)/IC50 (WT);
n  4. ND, not done. The following pyrimidine analogs were ineffective against promastigotes of either species (EC50 > 5000 mM): 5-ﬂuoroorotic acid, 5-chloro-20-deoxy-
uridine, 6-azauracil, 50-deoxy-50-ﬂuorouridine, 20 ,30-dideoxyuridine, 30-deoxyuridine, 2-thiouridine, 4-thiouridine, 5-chlorouridine, 5-iodouridine, 5-iodo-20-deoxyuridine, 5-
bromouracil, 5-bromouridine, 5-bromo-20-deoxyuridine, 5-ﬂuorocytosine, 5-ﬂuorocytidine.
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resistant Leishmania clones
As described in the Methods section, promastigotes of
L. mexicana and L. major were adapted by in vitro exposure to 5-FU
and 5F-20dUrd. It was noted that Leishmania cells were adapted to
5F-20dUrd more quickly than to 5-FU; while Leishmania cellsbecome insensitive to high concentrations of 5F-20dUrd in a few
months, the resistance induction to 5-FU required approximately
one year (Supplemental Fig. S2). Clonal lines were generated from
each strain that displayed resistance to high concentrations of 5-FU
or 5F-20dUrd. 5-FU-adapted clones from L. mexicana and L. major
were abbreviated Lmex-5FURes and Lmaj-5FURes, whereas cells
adapted to 5F-20dUrd were called Lmex-5F20dURes and Lmaj-
5F20dURes, respectively.
The anti-leishmanial activities and cross-resistance patterns of
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adapted cell line, in parallel with the parental wild-type control
strains (Table 3). It can be seen that Lmex-5FURes cells displayed
high levels of resistance to 5-FU, but retained the same sensitivity
to 5F-20dUrd. On the other hand, Lmex-5F20dURes were highly
cross-resistant to 5-FU and to 5F-20dCtd. As far as the L. major cell
lines are concerned, the 5-FU adapted cell line was only slightly
cross-resistant with 5F-20dUrd and, if anything, slightly more sen-
sitive to 5F-20dCtd, whereas the Lmaj5F20dURes clone was cross-
resistant to 5F-20dCtd but not to 5-FU.
Part of the resistance phenotype could be the result of changes
to the uptake efﬁciency of the ﬂuorinated pyrimidines and this was
therefore investigated next. Fig. 10 shows that in both of the 5-FU-
adapted clones, Lmex-5FURes and Lmaj-5FURes, 0.5 mM [3H]-uracil
transport was virtually absent, in contrast to solid levels of uptake
in the control wild-type cells. This is a strong indication that
resistance was the result of loss of the uracil transporter, a
conclusion further strengthened by the absence of [3H]-5-FU
transport in Lmex-5FURes but not wild-type cells (Fig. 10B). In
contrast, the uptake of [3H]-uridine was not affected in either of the
two resistant cell lines (Fig.10C,E), which shows that the adaptation
to 5-FU speciﬁcally involves the loss of the Leishmania U1 trans-
porters and does not affect the activity of NT1. Similarly, the
adaptation to 5F-20dUrd involved the complete or near-complete
abolition of uridine and adenosine uptake (Fig. 11A,B,D). In the
adapted cell line Lmex5F20dURes, uracil uptake was not affected at
all (Fig. 11C), whereas it was clearly reduced in Lmaj5F20dURes
(Fig. 11E), although not as much as uridine uptake was in these cellsFig. 10. Pyrimidine transport by Leishmania clones adapted to 5-FU. (A) Uptake of 0.5 mM [3
signiﬁcantly different from zero (P ¼ 0.0005, F-test).:,;: WT and Lmex5FURes, respective
which was 94.5% lower in Lmex5FURes than in WT cells, yet signiﬁcantly non-zero (P ¼ 0
Lmex5FURes than in WTcells (P > 0.05). (D) Uptake of 0.5 mM [3H]-uracil by Lmaj5FURes (,)
(P ¼ 0.027, F-test).:,;: WT and Lmaj5FURes, respectively, in the presence of 1 mM ura
Lmaj5FURes and WT cells (P > 0.05). Unit for transport was pmol(107 cells)1 in all frames
experiment, and error bars represent SEM.(Fig. 11D). From these results it is clear that the main adaptation to
5F-20dUrd in both Leishmania species was the drastic reduction of
NT1-mediated nucleoside transport. In addition, there was a large
reduction in LmajUU1 activity, which presumably further reduced
uptake of 5F-20dUrd.
3.6. Metabolomic investigation of the mechanism of action of
ﬂuorinated pyrimidines against Leishmania
The mechanism of action of the ﬂuorinated pyrimidines was
investigated using a metabolomics approach, where promastigotes
of L. mexicana and L. major were incubated for 8 h with 100 mM of
either 5-FU, 5F-20dUrd or 5F-Urd prior to metabolite extraction and
mass spectrometric analysis as described (Ali et al., 2013a; Alkhaldi
et al., 2015). These conditions were chosen to allow for signiﬁcant
metabolite accumulationwhile not affecting cell viability or growth
rate, which could broadly affect metabolite levels.
3.6.1. 5-ﬂuorouracil
As expected from the characterization of the Leishmania uracil
transport activities, promastigotes of L. mexicana and L. major
treated with 100 mM 5-FU contained a considerable amount of
intracellular 5-FU (Fig. 12A). Neither freshmedium nor intracellular
untreated controls showed any ﬂuorinated pyrimidines, conﬁrming
that these accurate mass LC-MS peaks are speciﬁc for the ﬂuori-
nated pyrimidines. 5F-20dUrd was detected in L. major, showing 5-
FU to be deoxyribosylated by a thymidine phosphorylase (5-FU
presumably functioning as a thymine analog), but for L. mexicanaH]-uracil by Lmex5FURes (,) was 90.2% lower than for WT control cells (C), but still
ly, in the presence of 1 mM uracil. (B) Like panel A, but with 0.5 mM [3H]-5-ﬂuorouracil,
.024). (C) Like panel A, but with 0.5 mM [3H]-uridine, which was only 4.0% lower in
was 95.7% lower than for WT control cells (C), but still signiﬁcantly different from zero
cil. (E) Like panel D, but with 0.5 mM [3H]-uridine, which was statistically identical in
; symbols represent the average of triplicate determinations in a single representative
Fig. 11. Pyrimidine transport by Leishmania clones adapted to 5-F20dUrd. (A) Uptake of 0.5 mM [3H]-uridine in Lmex5F20dURes cells (,) was 99% reduced compared to WT control
cells (C) and not signiﬁcantly different from zero (F-test, P ¼ 0.27).:,;: WT and Lmex5F20dURes, respectively, in the presence of 1 mM uridine. (B) Uptake of 0.1 mM [3H]-
adenosine in Lmex5F20dURes (,) was 89% lower than in WT control cells, but signiﬁcantly different from zero (P ¼ 0.0005).:,;: WT and Lmex5F20dURes, respectively, in the
presence of 1 mM adenosine. (C) Like frame A but measuring the uptake of 0.25 mM [3H]-uracil, which was not signiﬁcantly different in Lmex5F20dURes (,) and WT (C) cells.
:,;: WT and Lmex5F20dURes, respectively, in the presence of 1 mM uracil. (D) Uptake of 0.25 mM [3H]-uridine was 90.1% lower in Lmaj5F20dURes (,) than in WT control cells
(C), and signiﬁcantly different from zero (P ¼ 0.007).:,;: WT and Lmaj5F20dURes, respectively, in the presence of 1 mM uridine. (E) Uptake of 0.5 mM [3H]-uracil was 81.4%
lower in Lmaj5F20dURes (,) than in WT control cells (C), and signiﬁcantly different from zero (P ¼ 0.025).:,;: WT and Lmaj5F20dURes, respectively, in the presence of 1 mM
uracil. Unit for transport was pmol(107 cells)1 in all frames; symbols represent the average of triplicate determinations in a single representative experiment, and error bars
represent SEM.
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detected with this metabolomics workﬂow (Creek et al., 2012)
(Fig. 12B). However, L. mexicana also appears to generate 5F-20dUrd
from 5-FU, as almost identical levels of 5F-dUMP were observed in
both Leishmania species (Fig. 12C). This shows that 5F-20dUrd is a
substrate for Leishmania thymidine kinase, as reported previously
by Timm and coworkers (Timm et al., 2015), but no 5F-dUDP or 5F-
dUTP were detected in any of the samples. Another common aspect
between the Leishmania promastigotes was that neither 5-
ﬂuorouridine nor ﬂuorinated uridine ribonucleotides (5F-UMP,
5F-UDP and 5F-UTP) were observed in extracted 5-FU-treated
promastigotes, in complete contrast to 5-FUmetabolism inT. brucei,
where numerous such metabolites were found after exposure of
bloodstream forms to 5-FU (Ali et al., 2013a). We conclude that 5-
FU is not a substrate for Leishmania uracil phosphoribosyl trans-
ferase (UPRT), and that 5F-20dUrd is its only direct metabolite,
analogous to the deoxyribosylation of thymine to thymidine, by
uridine phosphorylase and/or by a separate thymidine phosphor-
ylase activity. This also implies that the detected deoxy 5-FU nu-
cleotides cannot have been derived from 5F-UDP via ribonucleotide
reductase.
The main metabolic change in 5-FU-treated cells was a change
in the level of deoxy-pyrimidine nucleotides. The intracellular
levels of dUMP in 5-FU-treated promastigotes of both species were
very strongly increased compared with respective untreatedcontrols. Indeed the dUMP level in untreated control cells was very
low, particularly in L. mexicana, where the level in untreated cells
was below automatic detection, precluding statistical analysis in
this instance (Fig. 12D). In addition, 5-FU caused a reduction in the
intensity of the dTMP and dTTP peaks in L. mexicana promastigotes
(P ¼ 0.05 and P ¼ 0.03, respectively, for L. mexicana compared with
respective untreated control) (Fig. 12E and F). It should be noted
that in treated L. major promastigotes the reduced level of deoxy-
thymidine nucleotides was not signiﬁcant, although a similarly
reduced dTTP level was observed in two out of three replicates. The
reduction in thymidine nucleotides could conceivably be the result
of a reduced rate of thymidine uptake; although the HOMEM me-
dium inwhich the experiment was performed does not contain any
thymidine, the added fetal bovine serum would be expected to
contain a small amount of thymidine. However, we found no sig-
niﬁcant difference in the free cellular thymidine levels between 5-
FU-treated and untreated cells. The reduction in thymidine nucle-
otides in Leishmania species is thus probably due to the inhibition of
thymidine kinase and thymidine synthase by 5-FU or, more likely,
its metabolites 5F-20dUrd and 5F-dUMP, which are analogous to
thymidine and TMP, respectively. It is the inhibition of dihy-
drofolate reductase-thymidine synthase (DHFR-TS), evidenced by
the massive build-up of dUMP in the cell, that may be the most
relevant as it is an essential enzyme in Leishmania (Titus et al.,
1995), and the target for antifolates such as methotrexate
Fig. 12. Metabolomic analysis of L. mexicana and L. major promastigotes treated for 8 h with 100 mM 5-FU. Hatched bars represent L. mexicana; solid bars, L. major. Panels AeC
represent the relative intensity, in arbitrary units, of 5-FU (A), 5F-20dUrd (B), or 5F-dUMP (C) in 5-FU-treated promastigotes. Panels DeH represent relative abundance of the
indicated metabolites in 5-FU-treated promastigotes and untreated control cells: dUMP (D); dTMP (E); dTTP (F); 20dUrd (G) and 20dAdo (H). The results are the mean and SEM of
triplicate determinations; *, P < 0.05, unpaired Student's t-test. Not detectable: the metabolite peak could not be identiﬁed in the sample with the requisite certainty. The dashed
line in Frame B indicates the detection limit, set at 500 units.
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and/or 5F-20dUrd inhibited thymidylate kinase, another key
metabolic enzyme (Thiel et al., 2008), explaining the reduced levels
of TTP.
Other changes that occurred in both L. mexicana and L. major
treated with 5-FU were an elevation of the levels of 20deoxyuridine
(Fig. 12G; P ¼ 0.06 and 0.05, respectively) and 20deoxyadenosine
(Fig. 12H; P < 0.05 for L. major) compared to untreated controls. We
also observed large increases in the intensity of 20deoxynucleotides
(dCMP, dCDP, dCTP, dAMP) relative to respective untreated controls
(Table 4). It must be noted that the level of 20deoxycytidine and
20deoxyadenosine nucleotides were barely detected in Leishmania
untreated controls; dATP was undetectable in both treated and
untreated cells; therefore, no statistical analysis can be performed
here and onwards. The increase in 20-deoxynucleosides andTable 4
Peak intensities of deoxynucleosides and nucleotides after metabolomic analysis.
L. major
Untreated þ5-FU þ5F20dUrd þ5FUrd
dCMP not detected 5130 not detected 6744 ± 3500
dCDP not detected 6197 ± 1588 6617 ± 188*** 6904 ± 384**
dCTP 995 ± 109 4541 ± 565 7036 ± 1684 5477 ± 1350*
dAdo 2992 ± 173 6996 ± 2423 14181 ± 3275 11818 ± 839**
dAMP 6192 ± 910 19379 ± 3774 14740 ± 2815 18001 ± 2307*
dADP not detected not detected 6493 ± 3261 6482 ± 3260
dUrd 712 ± 105 5177 ± 1445 7615 ± 1236* 8145 ± 1684*
Average (n ¼ 3) and SEM of peak intensities in arbitrary units as generated by the Orb
determined using an unpaired Student's t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Not d
deoxy nucleotides dTMP, dTTP, 20dUrd and dUMP have been depicted in Figs. 12e14.-nucleotides points to an effect on ribonucleotide reductase, which,
in T. brucei, is allosterically regulated by deoxynucleotides (Hofer
et al., 1998).
3.6.2. 5-Fluoro-20deoxyuridine
5F-20dUrd appears to be taken up robustly by promastigotes of
both Leishmania species, as intense peaks were detected in both
extracts after incubation with 100 mM of 5F-20dUrd for 8 h
(Fig. 13A). In addition, high levels of 5-FU were found after the
treatments (Fig. 13B), showing that the uridine phosphorylase/
thymidine phosphorylase catalyzes the reversible conversion of 5-
FU to 5F-20dUrd. As described above for the incubation with 5-FU,
no 5F-Urd was detected. 5F-dUMP was detected and the cellular
concentration was signiﬁcantly higher in L. mexicana than in
L. major (Fig. 13C), the difference likely being the result of a moreL. mexicana
untreated þ5-FU þ5F20dUrd þ5FUrd
not detected 5636 ± 3288 6006 ± 3089 12757 ± 1038**
not detected 4803 ± 433** 4451 ± 1188* 10404 ± 1470*
not detected 2913 ± 1346 1569 ± 244 2338 ± 428*
2585 ± 811 6476 ± 2403 5412 ± 1699 8045 ± 4537
10660 ± 2897 20366 ± 5358 30100 10459 21978 ± 1784**
1458 8948 ± 461** 8367 ± 1844* 9404 ± 1389*
304 ± 155 4166 ± 1560 5414 ± 717* 6439 ± 456*
itrap mass spectrometer. Statistical signiﬁcance relative to untreated controls was
etected implies that the signal was below 500 arbitrary units. The peak intensities of
Fig. 13. Metabolomic analysis of L. mexicana and L. major promastigotes treated for 8 h with 100 mM 5F-20dUrd. Hatched bars represent L. mexicana; solid bars, L. major. Panels AeC
represent the relative intensity, in arbitrary units, of 5F-20dUrd (A), 5-FU (B), or 5F-dUMP (C) in 5F-20dUrd -treated promastigotes. Panels DeH represent relative abundance of the
indicated metabolites in 5F-20dUrd -treated promastigotes and untreated control cells: dUMP (D); dTMP (E); dTTP (F); 20dUrd (G) and 20dAdo (H). The results are the mean and SEM
of triplicate determinations; *, P < 0.05; ***, P < 0.001 (unpaired Student's t-test). The dashed line in Frame F indicates the detection limit, set at 500 units.
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also consistent with the non-detection (depletion) of 5F-20dUrd in
5-FU-treated L. mexicana (Fig.12B), where 5F-20dUrdwas present at
a much lower level as it needed to be generated ﬁrst from 5-FU. The
higher level of 5F-20dUrd in L. mexicana also caused a stronger or
earlier inhibition of TS and a correspondingly higher level of dUMP
in the cells (Fig. 13D), although the treatment caused strong de-
pletions of dTMP and dTTP in both of the Leishmania species
(Fig. 13E and F); indeed, in 5F-20dUrd-treated L. mexicana, dTTP
could no longer be identiﬁed in any of the replicates.
As seen above with 5-FU, we also observed strong increases in
the level of 20deoxyuridine of both L. mexicana and L. major
(Fig. 13G; P < 0.001), and an increase in the 20deoxyadenosine in-
tensity (Fig. 13H; not signiﬁcant in L. mexicana, P ¼ 0.027 in
L. major). It was further observed that treatment with 5F-20dUrd,
like 5-FU, lead to similar increases in the levels of 20deoxycytidine
nucleotides (dCMP, dCDP, dCTP) and 20deoxyadenosine nucleotides
(dAMP, dADP) (Table 4).3.6.3. 5-Fluorouridine
5F-Uridine was clearly taken up by both species as it was easily
detectable intracellularly (Fig. 14A), although it was not observed in
cells treated with 5-FU or 5F-20dUrd. In both species, by far the
highest intensity peak of a ﬂuorinated pyrimidine was 5-FU
(Fig. 14B), indicating that 5F-Urd was a substrate for a uridine
phosphorylase and/or thymidine phosphorylase although it is notgenerated by it to any detectable level from 5-FU, indicating that
the reaction equilibrium is strongly towards the phosphorolysis of
5F-Urd. Relatively low intensity peaks for 5F-20dUrd (L. major;
Fig. 14C) and 5F-dUMP (L. mexicana; Fig. 14D) were also observed.
The higher level of 5F-dUMP in L. mexicanawas also observed after
treatment with 5F-20dUrd (Fig. 13D) and, together with the below
detection level of 5F-20dUrd in cells treated with either 5-FU or 5F-
Urd (Fig. 12B and Fig. 14C, respectively), strongly suggest that 5F-
20dUrd is a better substrate for thymidine kinase in L. mexicana than
in L. major, leading to a build-up of 5F-20dUrd in L. major but not in
L. mexicana.
As with the other treatments, very large increases in dUMP
levels were observed (Fig. 14E), and the intensity of thymidine
nucleotides was decreased (Fig. 14F and G), although the latter
changes were relatively minor compared to 5-FU and 5F-20dUrd
treatment. Interestingly, the peak intensities for 5F-dUMP and
dUMP were much higher in L. mexicana than in L. major, although
L. mexicana was insensitive to 5F-Urd up to 5 mM (Table 3). This
seems to indicate that, at least in L. mexicana, high levels of dUMP
alone are not sufﬁcient to cause cell death, and that the depletion of
dTTP is a better marker of the antileishmanial activity of ﬂuorinated
pyrimidines. Both species showed a similar increase in 20-dUrd
peak intensity (Fig. 14H) but only L. major showed a signiﬁcant
increase in 20-deoxyadenosine (Fig. 14I); however, both species
contained signiﬁcantly increased levels in deoxycytidine nucleo-
tides, dAMP and dADP (Table 4).
Fig. 14. Metabolomic analysis of L. mexicana and L. major promastigotes treated for 8 h with 100 mM 5F-Urd. Hatched bars represent L. mexicana; solid bars, L. major. Panels AeC
represent the relative intensity, in arbitrary units, of 5F-Urd (A), 5-FU (B), 5F-20dUrd (C), or 5F-dUMP (D) in 5F-Urd-treated promastigotes. Panels EeI represent relative abundance of
the indicated metabolites in 5F-Urd-treated promastigotes and untreated control cells: dUMP (E); dTMP (F); dTTP (G); 20dUrd (H), 20dAdo (I). The results are the mean and SEM of
triplicate determinations; *, P < 0.05; ***, P < 0.001 (unpaired Student's t-test). The dashed line in Frames C and D indicates the detection limit, set at 500 units.
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Nucleotide metabolism in protozoa is replete with promising
drug targets, and nucleoside analogs have become key players in
anticancer and anti-viral chemotherapy. In Trypanosoma brucei,
purine and pyrimidine transporters have been studied in great
detail, as have many enzymes of nucleotide metabolism (De Koning
and Jarvis, 1998; De Koning et al., 2005; Al-Salabi et al., 2007; Berg
et al., 2010a, 2010b; Munday et al., 2013). This information is now
being translated into the rational design of nucleoside analogs, with
efﬁcient uptake through known transporters and well-understood
metabolic activation steps, as potential agents against African
trypanosomiasis (Berg et al., 2010a; Vodnala et al., 2013, 2016;
Rodenko et al., 2015; Ranjbarian et al., 2017). Developing new
drugs for the leishmaniases, with their multiple pathologies and
many causative species, is at least as urgent; yet the current
knowledge of Leishmania purine and pyrimidine transporters and
metabolism lags behind that of African trypanosomes. In this study
we attempt to address several of the urgent questions pertinent to
the development of a successful nucleoside-analog therapy against
leishmaniasis: (1) Are the nucleoside transporters in various clini-
cally important Leishmania species similar enough to allow the
efﬁcient uptake of the same analogs? (2) Would the Leishmania
nucleoside transporters, like their T. brucei counterparts, allow the
uptake of modiﬁed nucleosides and if so, which modiﬁcations
might be admissible? (3) How susceptible is the pyrimidine salvage
system to pyrimidine analogs, including 5-halogenated pyrimi-
dines that have beenwidely used in anti-cancer chemotherapy, and
could these be repurposed? (4) How are such pyrimidine analogs
metabolized in Leishmania, are there signiﬁcant differences be-
tween species, and how does this compare to the same process inAfrican trypanosomes?
Since more than 20 different Leishmania species contribute to
the various clinical manifestations of leishmaniasis world-wide, it
is virtually essential that any new treatments developed should be
efﬁcacious to at least the main pathogenic species involved, and
this issue should be addressed at the very onset of a program,
before major resources are invested in a strategy. In that context we
address here whether nucleoside transport in L. mexicana and
L. major are substantially different from each other, and from the
L. donovani transporters reported earlier (see Introduction). The
three ENT-family nucleoside transporters (NT1.1, NT1.2 and NT2)
seem to be syntenically preserved throughout the genus. We
cloned these genes from L. mexicana and L. major, and expressed
them heterologously in the related trypanosomatid T. brucei. The
results show that, as in L. donovani (Vasudevan et al., 1998; Carter
et al., 2000), the NT1 transporters mediate the uptake of uridine
and adenosine but not inosine, whereas the NT2 transporters
facilitate inosine but not uridine uptake. Thus, we conclude that the
organization of nucleoside transport is preserved in Leishmania
species causing mainly visceral (L. donovani), ‘old world’ cutaneous
(L. major) and diffuse cutaneous and muco-cutaneous ‘new world’
leishmaniasis (L. mexicana).
Functional studies with L. donovani promastigotes and individ-
ual L. donovani nucleoside transporters expressed in Xenopus laevis
oocytes established that LdNT1.1 was a higher afﬁnity transporter
than LdNT1.2 (Vasudevan et al., 1998; Landfear, 2001), with NT1.1
displaying Km values of ~0.2 mM and 5 mM for adenosine and uri-
dine, respectively, whereas the corresponding values for NT1.2
were ~5 mM and 40 mM, respectively. It was further reported that
expression of NT1.2 was very low in promastigotes, contributing
relatively little to the nucleoside transport activity. These
K.J.H. Alzahrani et al. / International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 206e226 223observations are entirely compatible with our careful analysis of
nucleoside uptake in promastigotes of L. major and L. mexicana, as
we present clear evidence for a higher afﬁnity and a lower afﬁnity
adenosine-sensitive uridine uptake activity. In both cases, the
higher afﬁnity transport was sensitive to inhibition by uracil, and at
least in the case of L. mexicana, it was able to transport this
nucleobase, and we therefore named this activity L. mexicana
uridine-uracil transporter 1 (LmexUUT1), rather than NT1.1. How-
ever, the UU1 transporters of L. mexicana and L. major clearly are
high afﬁnity adenosine/uridine transporters, with a secondary
ability to transport uracil (in L. mexicana Vmax/Km [3H]-
uracil¼ 0.003, compared to 0.14, 1.38 and 0.055 for [3H]-thymidine,
[3H]-adenosine and [3H]-uridine, respectively), and are thus
nucleoside transporters rather than nucleobase transporters. For
L. donovani it was never tested whether either of the NT1-type
transporters might be sensitive to inhibition by uracil, but by
extension it could be speculated that LdNT1.1might be homologous
to LmexUUT1 and LdNT1.2 the equivalent of LmexNT1; this remains
to be established. LmexUUT1 was sensitive to both thymidine and
adenosine, as shown above for the equivalent activity LmajUUT1. In
L. major, it was possible to detect two separate thymidine transport
activities with Km values of 4.2 mM and 26.9 mM, respectively. Thus,
all three Leishmania species express 2 uridine transporters, which
are also transporters for adenosine and thymidine (Fig. 15). In
addition, L. major, at least, is reported to express two purine
nucleobase transporters, LmajNT3 and LmajNT4 (Sanchez et al.,
2004; Ortiz et al., 2007), as well as a high afﬁnity (Km ¼ 0.32 mM)
uracil transporter, LmajU1 (Papageorgiou et al., 2005).Fig. 15. Schematic model of pyrimidine transport activities in L. mexicana (top panel) and L.
arrow heads pointing to intracellular space. Each box-arrow represents a transport activity,
were not tested in this study or of low afﬁnity are listed in brackets.We next addressed whether these transporters might allow the
accumulation of cytotoxic nucleosides in Leishmania parasites.
Previous authors had already shown uptake of the purine nucleo-
side analogs 7-deaza-adenosine (tubercidin) by LdNT1.1
(Vasudevan et al., 1998; Landfear, 2001) and of Formycin B by
LdNT2 (Carter et al., 2000), as well as inhibition by 6-thioguanosine
at 100-fold excess over inosine as a substrate (Carter et al., 2000).
Here we tested a number of pyrimidine nucleoside analogs for in-
hibition of LmajNT1 and found that 5F-Urd and 5F-20dUrd, in
particular, but also 4-thiouridine and 5F-50dUrdwere able to inhibit
this transporter. Using these and other results, we were able to
construct a model for pyrimidine nucleoside binding by LmajNT1,
which should assist in the further selection of possible substrates
for this carrier, much as it has done for some of the T. brucei
transporters for which we constructed similar models (Lüscher
et al., 2007b; Chollet et al., 2009; Vodnala et al., 2013; Rodenko
et al., 2015).
We further tested a series of pyrimidine nucleoside analogs for
activity against L. mexicana and L. major promastigotes, and found
several things of interest. First, we found that of 21 analogs tested,
20 exhibited highly similar activities against both species, with 5F-
Urd being the sole exception as L. mexicana was completely unaf-
fected by it (although it was clearly taken up, being detected
intracellularly by the metabolomic analysis). Indeed, we found that
4-thiouridine and 5F-50dUrd (which like 5F-Urd are inhibitors of
LmajNT1) had no effect on promastigotes even at millimolar levels.
This highlights a key challenge to developing a rational nucleoside
therapy to protozoa, i.e. analogs must be compatible both with themajor (lower panel). The blue bars represent the parasite plasma membranes, with the
identiﬁed in bold red font, with substrates listed underneath; expected substrates that
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metabolic enzymes that are required to activate these prodrugs.
Nonetheless, 5-FU, 5F-20dCtd, and in particular 5F-20dUrd, showed
activity against both Leishmania species in the low-micromolar
range. In this the Leishmania promastigotes were surprisingly
similar to bloodstream form T. brucei: 5-FU, 5F-20dUrd and 5F-
20dCtd were much more active against the trypanosomes than any
of the other halogenated pyrimidines tested against those parasites
(Ali et al., 2013a). The main difference between the Leishmania
species and T. brucei, with regards to sensitivity to pyrimidine an-
alogs, is that Leishmania promastigotes are insensitive to 5F-orotic
acid, to which the trypanosomes are susceptible. This can be un-
derstood in the context of a pyrimidine auxotrophic clone
L. donovani being unable to grow in 100 mM orotate as sole py-
rimidine source (French et al., 2011), being unable to incorporate
this precursor of UMP (in contrast to T. brucei (Ali et al., 2013b)).
Fluorinated pyrimidines have previously been introduced as
pyrimidine salvage inhibitors against T. gondii (Youn et al., 1990)
and L. amazonensis (Katakura et al., 2004). Here we do not neces-
sarily propose ﬂuorinated pyrimidines as antileishmanial lead
compounds; rather, this study is the ﬁrst effort to evaluate the
metabolism of pyrimidine anti-metabolites by Leishmania para-
sites, and the mechanism by which they might exert their anti-
leishmanial effects. We were able to adapt the Leishmania
promastigotes to high levels of resistance to ﬂuorinated pyrimi-
dines. The cell lines adapted to 5F-20dUrd were cross-resistant to
5F-20dCtd, as has been reported also for T. brucei (Ali et al., 2013a),
which highlights that the deoxy nucleoside analogs likely have the
same mechanism of action (5F-20dCtd being converted to 5F-
20dUrd by cytidine deaminase) as well as the same transporters.We
also show here that in both Leishmania species, the 5-FU adaptation
was associated with a near-complete ablation of uracil and 5-FU
uptake, whereas uptake of uridine was not signiﬁcantly affected.
Similarly, the 5F-20dUrd-resistant strains had lost >90% of uridine5F-uraci
5F-UMP
5F-UDP
5F-UTP
5F-CTP
5F-uridine
5F-uraci5F-uridine
5F-UDP-Glc
5F-UDP-Gal
5F-UDP-GlcNAc
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9
5
4
3
21
Fig. 16. Schematic overview of ﬂuoropyrimidine metabolism in T. b. brucei and Leishmania sp
in both T. brucei and Leishmania species; Blue boxes and arrows are observed only in T. bruc
boxes and arrows indicate reactions that do not happen in either species. The curved blue ba
indicated with numbers as follows. 1, Uridine Phosphorylase and/or Thymidine Phosphory
Diphosphate Kinase; 5, Cytidine Triphosphate Synthase; 6, Ribonucleoside-diphosphate Red
1-phosphate Uridylyltransferase; 10, UDP-Glucose Pyrophosphorylase; 11, UDP-Glucose Ep
lyltransferase; 14, Choline-phosphate Cytidylyltransferase; 15, RNA Polymerase.(and adenosine) uptake capacity, whereas uracil uptake in Lmex-
5F20dURes was unaffected, but 80% lower in Lmaj-5F20dURes. We
conclude that loss of NT1-like transport activity can account for
much of the resistance phenotype. It has previously been shown
that the Leishmania nucleoside transporters are not essential pro-
teins under standard in vitro or in vivo conditions (Liu et al., 2006).
Apart from the details of pyrimidine transport, the pyrimidine
salvage pathways are believed to be identical in the various path-
ogenic kinetoplastids (Valente et al., 2016). However, we found that
ﬂuorinated pyrimidines were metabolized by strikingly different
routes and caused different metabolic effects in Leishmania pro-
mastigotes when compared to those reported previously in
T. brucei. In T. brucei (Fig. 16), 5-FU was a substrate for UPRT and
incorporated into uridine ribonucleotides and RNA and other me-
tabolites derived from uridine nucleotides, including CTP, lipid in-
termediates such as CDP-ethanolamine, and glycosylation
intermediates such as UDP-hexoses/hexosamines (Ali et al., 2013a).
In contrast, we show here that 5-FU is not a substrate for LmajUPRT
or LmexUPRT as no ﬂuorinated ribonucleotides could be detected,
including 5F-UMP. Instead, the only primary metabolite of 5-FU
detected in Leishmania promastigotes was 5F-20dUrd, consistent
with reports that Leishmania species contain “a thymidine phos-
phorylase activity” (LaFon et al., 1982). We propose that Leishmania
UP might recognize both uridine and thymidine, and hence
5F,20dUrd, a thymidine analogue; alternatively there could be
separate phosphorylases for thymidine and uridine. The deoxy-
ribosylation of 5-FU to 5F,20dUrd requires a source of deoxyribose-
1-phosphate, which is not normally highly abundant in the cell. We
speculate that the elevated levels of 20-deoxynucleotides detected
in the metabolomic analyses, particularly dUMP, are the result of
increased activity of ribonucleotide reductase and inhibition of
thymidylate synthase, and that increased phosphorolysis of these
excess deoxynucleotides may generate a source of deoxyribose-1-
phosphate used in forming 20dUrd from 5-FU. The 5F-20dUrd isl 5F-2’dUrd
5F-2’dUMP
5F-2’dUDP
l 5F-2’dUrd
Lipid metabolism
RNA
5F-2’dUDP
1 8
7
15
6
12, 13, 14
ecies. Red boxes and arrows represent metabolites and reactions, respectively, observed
ei and green arrows represent reactions observed only in the Leishmania species; black
r schematically represents the plasma membrane of the parasites. Enzyme reactions are
lase; 2, Uracil Phosphoribosyl transferase; 3, Nucleoside Diphosphatase; 4, Nucleoside
uctase; 7, Thymidylate Kinase; 8, Thymidine Kinase; 9, UTP:N-acetyl-a-D-glucosamine-
imerase; 12, Phosphatidate Cytidylyltransferase; 13, Ethanolamine-phosphate Cytidy-
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ported in T. brucei (Ali et al., 2013a), which in turn inhibits thymi-
dylate synthase (DHFR-TS) and gives rise to an accumulation of
dUMP and further changes in deoxynucleotide metabolism, pre-
sumably through interferencewith the regulation of ribonucleotide
reductase. Treatment with 5F-Urd followed the same metabolomic
pattern, with the nucleoside ﬁrst non-reversibly converted to 5-FU.
This model for the trypanocidal activity of ﬂuorinated pyrimi-
dines is compatible with observations made by Ritt and coworkers
(Ritt et al., 2013), who sequenced a number of 5-FU-adapted
L. infantum. They found the ampliﬁcation of DHFR-TS as one main
adaptation, in addition to point mutations in UP and TK, all
consistent with our model. However, they also found point muta-
tions in LinfUPRT, although we found no evidence of this enzyme
being involved in 5-FUmetabolism in L. mexicana and L. major. One
explanation might simply be that 5-FUmetabolism in L. infantum is
different in this respect, but unlike UP and TK, the reintroduction of
a wild-type copy of LinfUPRT only marginally reversed the resis-
tance phenotype, and the authors point out that the same resistant
strain had also lost all capacity for 5-ﬂuorouracil uptake, implying
that the UPRT mutation may have been an early mutation during
the adaptation, conferring a marginal advantage that was super-
seded by a subsequent loss of transport activity (Ritt et al., 2013).
Altogether we conclude that, like nucleoside transport, the mech-
anism of action of 5-ﬂuoro pyrimidines is essentially conserved in
multiple Leishmania species covering most of the spectrum of
leishmaniasis pathologies. Finally, we propose that 5F-20dUrd is a
more promising therapeutic lead against leishmaniasis, as the
nucleoside display a more potent anti-leishmanial activity, is efﬁ-
ciently quickly taken up the parasites, and does not require the UP
activation step.
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